Prognostic factors of mortality and cardiovascular outcomes in the tiotropium safety and performance in respimat (TIOSPIR) trial
R. Dahl, D. Dusser, R. Wise, G. Pledger, A. Anzueto, A. Mueller, A. Fowler, P. Calverley (Odense, Denmark; Sorbonne Paris Cité, Paris, France; Baltimore, Hamilton, San Antonio, United States Of America; Ingelheim, Germany; Bracknell, Liverpool, United Kingdom)
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Session: New clinical evidence for asthma and COPD treatments
Session type: Thematic Poster Session
Number: 2421
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Dahl, D. Dusser, R. Wise, G. Pledger, A. Anzueto, A. Mueller, A. Fowler, P. Calverley (Odense, Denmark; Sorbonne Paris Cité, Paris, France; Baltimore, Hamilton, San Antonio, United States Of America; Ingelheim, Germany; Bracknell, Liverpool, United Kingdom). Prognostic factors of mortality and cardiovascular outcomes in the tiotropium safety and performance in respimat (TIOSPIR) trial. Eur Respir J 2014; 44: Suppl. 58, 2421
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: